financetom
MIR
financetom
/
Industrials
/
MIR
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Mirion Technologies, Inc.MIR
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, South Korea, and Japan.

It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products.

This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation.

The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools.

The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services.

It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs.

The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006.

The company was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Latest News >
Apple Shipments Fail to Match Global Smartphone Sales Growth
Apple Shipments Fail to Match Global Smartphone Sales Growth
Nov 27, 2024
06:55 AM EST, 11/27/2024 (MT Newswires) -- Apple ( AAPL ) failed to benefit from a forecast 6.2% global rise in smartphone shipments in 2024, an International Data Corporation quarterly report said Tuesday. Apple's ( AAPL ) iOS is expected to grow a modest 0.4% in 2024, stymied by challenges in China, the US, and Europe, the report said. Meanwhile,...
Quarterhill Wins Two Contracts in Idaho Worth US$3.4 Million for Weigh Station Upgrades, Maintenance
Quarterhill Wins Two Contracts in Idaho Worth US$3.4 Million for Weigh Station Upgrades, Maintenance
Nov 27, 2024
06:54 AM EST, 11/27/2024 (MT Newswires) -- Quarterhill ( QTRHF ) on Wednesday said it has been awarded two contracts valued at US$3.4 million for system upgrades and maintenance at commercial vehicle enforcement stations operated by the Idaho State Police. Quarterhill ( QTRHF ) has been contracted by the Idaho Transportation Department to install new components and upgrade the Inkom...
Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details
Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details
Nov 27, 2024
Frontline Plc ( FRO ) shares are down following mixed third-quarter results. Revenue rose 29.9% year-over-year to $490.4 million, surpassing the $361.42 million consensus. Reported spot TCEs for VLCCs, Suezmax tankers, and LR2/Aframax tankers were $39,600 (vs. $42,500 last year), $39,900 (vs. $37,600 last year) and $36,000 (vs. $33,900 prior year) per day. In the quarter, ballast days totaled 947...
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients
Nov 27, 2024
06:56 AM EST, 11/27/2024 (MT Newswires) -- BeiGene Ltd ( BGNE ) said Wednesday that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. The approval is based on results from BeiGene's ( BGNE ) RATIONALE-306 and RATIONALE-305 phase 3 trials, which evaluated the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved